Skip to main content
Top

09-06-2024 | Human Immunodeficiency Virus | Original Paper

Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial

Authors: Kenneth Ngure, Erica N. Browne, Krishnaveni Reddy, Barbara A. Friedland, Ariane van der Straten, Thesla Palanee-Phillips, Rita Nakalega, Brenda Gati, Hadijah N. Kalule, Bekezela Siziba, Lydia Soto-Torres, Gonasagrie Nair, Morgan Garcia, Connie Celum, Sarah T. Roberts

Published in: AIDS and Behavior

Login to get access

Abstract

We evaluated correlates of adherence to PrEP, including daily oral tenofovir disoproxil fumarate in combination emtricitabine (oral FTC/TDF) and the monthly dapivirine ring (ring)among adolescent girls and young women (AGYW) in the MTN-034/REACH study. We enrolled 247 AGYW aged 16–21 years in South Africa, Uganda and Zimbabwe (ClinicalTrials.gov: NCT03074786). Participants were randomized to the order of oral FTC/TDF or ring use for 6 months each in a crossover period, followed by a 6-month choice period. We assessed potential adherence correlates—individual, interpersonal, community, study, and product-related factors—quarterly via self-report. We measured biomarkers of adherence monthly; high adherence was defined as > 4 mg dapivirine released from returned rings or intracellular tenofovir diphosphate levels ≥ 700 fmol/punch from dried blood spots (DBS). We tested associations between correlates and objective measures of high adherence using generalized estimating equations. High adherence to oral FTC/TDF was significantly associated with having an older primary partner (p = 0.04), not having exchanged sex in the past 3 months (p = 0.02), and rating oral FTC/TDF as highly acceptable (p = 0.003). High ring adherence was significantly associated with unstable housing (p = 0.01), disclosing ring use to a male family member (p = 0.01), and noting a social benefit from study participation (p = 0.03). All associations were moderate, corresponding to about 6%–10% difference in the proportion with high adherence. In our multinational study, correlates of adherence among African AGYW differed for oral FTC/TDF and the ring, highlighting the benefit of offering multiple PrEP options.
Appendix
Available only for authorised users
Literature
4.
go back to reference J. B. Marrazzo, M,; Bekker LG, Celum, C.; Kiragu, M.; Leech, A.A.; Taylor, A.; Ussery, F.; Yang, J.; de Boer, M.; Carter, C.; Das, M.; Baeten,J.M.; Tao, L. 8+ years pooled analysis: Adherence and HIV incidence in >6000 women on F/TDF for PrEP. Oral presentation at the 30th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, 2023: Abstract 163. J. B. Marrazzo, M,; Bekker LG, Celum, C.; Kiragu, M.; Leech, A.A.; Taylor, A.; Ussery, F.; Yang, J.; de Boer, M.; Carter, C.; Das, M.; Baeten,J.M.; Tao, L. 8+ years pooled analysis: Adherence and HIV incidence in >6000 women on F/TDF for PrEP. Oral presentation at the 30th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, 2023: Abstract 163.
34.
go back to reference Nakigudde J, Musisi S, Ehnvall A, Airaksinen E, Agren H. Adaptation of the multidimensional scale of perceived social support in a Ugandan setting. Afr Health Sci. 2009;9:35–41. Nakigudde J, Musisi S, Ehnvall A, Airaksinen E, Agren H. Adaptation of the multidimensional scale of perceived social support in a Ugandan setting. Afr Health Sci. 2009;9:35–41.
36.
go back to reference B. A. F. Kenneth Ngure, Daniel W. Szydlo, Sarah T. Roberts, Morgan Garcia, Lisa Levy, Carolyne A. Akello, Krishnaveni Reddy, Thesla Palanee-Phillips, Pippa Macdonald, Bekezela Siziba, Lydia Soto-Torres, Sybil Hosek, Sharon L. Hillier, Gonasagrie Nair, Connie Celum, Ariane van der Straten., “Baseline Preferences for Oral Pre-exposure Prophylaxis (PrEP) or Dapivirine Intravaginal Ring for HIV Prevention among Adolescent Girls and Young Women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 Study) (In Press),” PLoS ONE. B. A. F. Kenneth Ngure, Daniel W. Szydlo, Sarah T. Roberts, Morgan Garcia, Lisa Levy, Carolyne A. Akello, Krishnaveni Reddy, Thesla Palanee-Phillips, Pippa Macdonald, Bekezela Siziba, Lydia Soto-Torres, Sybil Hosek, Sharon L. Hillier, Gonasagrie Nair, Connie Celum, Ariane van der Straten., “Baseline Preferences for Oral Pre-exposure Prophylaxis (PrEP) or Dapivirine Intravaginal Ring for HIV Prevention among Adolescent Girls and Young Women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 Study) (In Press),” PLoS ONE.
52.
go back to reference Roberts ST, Mancuso N, Williams K, Kalule HN, Mposula H, Mugocha C, Mvinjelwa P, Garcia M, Szydlo D, Soto-Torres L, Ngure K, Hosek S. Strategies to support effective use of the vaginal ring and oral PrEP among adolescent girls and young women in sub-Saharan Africa: Qualitative findings from MTN-034/REACH. J Int AIDS Soc. 2022;25:183–4. Roberts ST, Mancuso N, Williams K, Kalule HN, Mposula H, Mugocha C, Mvinjelwa P, Garcia M, Szydlo D, Soto-Torres L, Ngure K, Hosek S. Strategies to support effective use of the vaginal ring and oral PrEP among adolescent girls and young women in sub-Saharan Africa: Qualitative findings from MTN-034/REACH. J Int AIDS Soc. 2022;25:183–4.
Metadata
Title
Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial
Authors
Kenneth Ngure
Erica N. Browne
Krishnaveni Reddy
Barbara A. Friedland
Ariane van der Straten
Thesla Palanee-Phillips
Rita Nakalega
Brenda Gati
Hadijah N. Kalule
Bekezela Siziba
Lydia Soto-Torres
Gonasagrie Nair
Morgan Garcia
Connie Celum
Sarah T. Roberts
Publication date
09-06-2024
Publisher
Springer US
Published in
AIDS and Behavior
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-024-04382-3
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare